Matt Miksic from Barclays lowered the price target on Becton, Dickinson, and Company (NYSE:BDX) from $261 to $241, while ...

Enrollment in a patient-delivered intervention allowed adults with overweight or obesity to better maintain weight loss than ...

Morgan Stanley has lowered its price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $755 from $958, while ...

Nifty 50 is currently trading at 20.2 times one-year forward price-to-earnings ratio (PER), slightly below its five-year ...

JPMorgan analysts increased the price target for CrowdStrike Holdings, Inc. (NASDAQ:CRWD) stock to $500 from $450 and ...

It will be tougher to generate alpha or excess returns over an underlying benchmark over the medium term, says Shah ...

This study shows that midlife weight loss, without medical interventions, reduces chronic disease risk and supports longevity ...

The John Hancock Multimanager 2035 Lifetime Portfolio fund underperformed its benchmark for Q1 of 2025. Click here to read ...

Piper Sandler lifted the price target on NVIDIA Corporation (NASDAQ:NVDA) stock from $150 to $180, reaffirming its Overweight ...

Barclays maintained an “Overweight” rating on PDD Holdings Inc. (NASDAQ:PDD) and kept a price target of $158. This decision ...

The percentage of overweight or obese adults prescribed GLP-1s jumped by almost 587% between 2019 and 2024, according to a ...